Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Hordaland Health Study (HUSK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03013725
Recruitment Status : Completed
First Posted : January 6, 2017
Last Update Posted : January 6, 2017
Sponsor:
Collaborator:
Part of CONOR, and participates in the Norwegian Epidemiologic Osteoporosis Studies
Information provided by (Responsible Party):
Grethe Seppola Tell, University of Bergen

Brief Summary:

The Hordaland Health Studies (HHS) were conducted in 1992-93 (The Homocysteine study) and in 1997-99 (HUSK). Both surveys were conducted as a joint project between the University of Bergen, the Norwegian Health Screening Service (SHUS) (now part of the National Institute of Public Health) and the Municipal Health Service in Hordaland.

The main focus of the studies is on chronic diseases including cardiovascular disease, cancer, osteoporosis, anxiety and depression. Some projects focus on psychosocial factors, occupational research, musculoskeletal diseases, urinary incontinence and mapping of drug use. The main purpose of the surveys is to gather information so that disease ultimately can be prevented.

Approximately 36,000 residents of Hordaland county participated in the studies, ca. 18,000 in 1992-93 and ca. 26,000 in 1997-99. About 7,000 of those who participated in the 1992-93 survey also participated in 1997-99.


Condition or disease Intervention/treatment
Chronic Disease Other: No intervention

Layout table for study information
Study Type : Observational
Actual Enrollment : 36000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Hordaland Health Studies (HHS)
Study Start Date : January 1992
Actual Primary Completion Date : June 1999
Actual Study Completion Date : June 1999

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
The Homocysteine Study
Conducted in 1992-93, ca. 18000 participated.
Other: No intervention
No intervention

The Hordaland Health Study (HUSK)
Conducted in 1997-99, ca. 26000 participated.
Other: No intervention
No intervention




Primary Outcome Measures :
  1. Total mortality. [ Time Frame: Participants are followed from baseline (1992-93 or 1997-99) until death or December 31st, 2015. ]
    The unique 11-digit personal identification number assigned to all Norwegian residents facilitates linkage between HHS and the Norwegian Population Register, which contains information on vital status (alive, emigrated, or dead). The follow-up period varies from 16 - 23 years, depending on whether first or second measurement is used as baseline.


Secondary Outcome Measures :
  1. Mortality or morbidity from chronic diseases (for example cardiovascular disease, cancer). Also, award of disability pension are used as an outcome. [ Time Frame: Participants are followed from baseline (1992-93 or 1997-99) until time of diagnosis/death from disease or the last day of follow-up. ]

    The Cause of Death Registry, Cancer Registry of Norway, CVDNOR and FD-trygd (a national database of Health and social benefits) will be used to get information on outcomes. The last day of follow-up for cardiovascular disease is December 31st, 2014. The last day of follow-up for cancer is December 31st, 2014.

    The last day of follow-up for Cause of Death is December 31st, 2014. The follow-up period for cardiovascular disease varies from 15 - 22 years, depending on whether first or second measurement is used as baseline.

    The follow-up period for cancer varies from 15 - 22 years, depending on whether first or second measurement is used as baseline.



Biospecimen Retention:   Samples Without DNA
Blood samples are stored at two biobanks located in Bergen and Levanger. The blood was divided in full blood, plasma and serum.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Approximately 36,000 residents of Hordaland county participated in the studies (both men and women), ca. 18,000 in 1992-93 and ca. 26,000 in 1997-99. About 7,000 of those who participated in the 1992-93 survey also participated in 1997-99.
Criteria

Inclusion Criteria:

  • Born in a specific time-period
  • From Hordaland County
  • Community-dwelling people who were able to come to the study site on their own, and able to fill out questionnaires.

Exclusion Criteria:

  • Not born within the specific time-period
  • Not from Hordaland County
  • Institutionalized People
  • People who were not able to fill out questionnaires
Additional Information:
Study Data/Documents: Study Protocol  This link exits the ClinicalTrials.gov site
Protocol

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Grethe Seppola Tell, Professor, University of Bergen
ClinicalTrials.gov Identifier: NCT03013725    
Other Study ID Numbers: HUSK9799
First Posted: January 6, 2017    Key Record Dates
Last Update Posted: January 6, 2017
Last Verified: January 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Disease
Disease Attributes
Pathologic Processes